Condition

Stage IV Breast Cancer AJCC v6 and v7

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 52 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials52

Recruiting3

Common interventions25

Lead sponsors shown11

Clinical trials

52 shown

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast CancerNCT04521764 · 2020-09-23

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted TherapyNCT04692103 · 2021-07-10

ACTIVE_NOT_RECRUITING

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05

Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerNCT03633331 · 2018-08-15

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerNCT03377101 · 2018-08-07

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast CancerNCT03477396 · 2018-06-14

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNCT03326258 · 2018-04-20

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerNCT03432741 · 2018-03-27

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityNCT03428802 · 2018-03-08

ACTIVE_NOT_RECRUITING

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerNCT03101748 · 2018-02-19

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerNCT03012230 · 2017-12-06

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine TherapyNCT03281902 · 2017-11-13

ACTIVE_NOT_RECRUITING

Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast CancerNCT03535701 · 2017-10-20

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerNCT03106415 · 2017-09-27

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerNCT02971761 · 2017-06-01

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast CancerNCT02673398 · 2016-12-02

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerNCT02778685 · 2016-09-30

ACTIVE_NOT_RECRUITING

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesNCT02595905 · 2016-09-15

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNCT02498613 · 2016-08-31

ACTIVE_NOT_RECRUITING

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordNCT02713269 · 2016-08-29

ACTIVE_NOT_RECRUITING

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryNCT02658812 · 2016-08-01

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine TherapyNCT02398773 · 2016-05-04

ACTIVE_NOT_RECRUITING

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesNCT02706392 · 2016-03-16

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerNCT02474173 · 2016-01-15

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerNCT02311933 · 2015-05-28

ACTIVE_NOT_RECRUITING

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianNCT02208375 · 2014-11-11

ACTIVE_NOT_RECRUITING

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsNCT02152943 · 2014-07-17

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast CancerNCT02037529 · 2014-01-17

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer TherapyNCT01957514 · 2013-10-28

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerNCT01622868 · 2012-12-06

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNCT01552434 · 2012-10-16

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerNCT01624441 · 2012-08-21

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · 2012-08-03

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast CancerNCT01463072 · 2012-06-19

ACTIVE_NOT_RECRUITING

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyNCT01434303 · 2012-01-10

Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerNCT01349959 · 2011-08-15

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT01351909 · 2011-05-02

ACTIVE_NOT_RECRUITING

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerNCT01344031 · 2011-04-21

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast CancerNCT01327781 · 2011-03-25

ACTIVE_NOT_RECRUITING

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerNCT01251874 · 2010-11-22

ACTIVE_NOT_RECRUITING

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerNCT01217411 · 2010-10-01

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyNCT02149173 · 2010-09-15

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerNCT01145430 · 2010-06-01

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerNCT01142401 · 2010-05-26

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerNCT00699491 · 2008-10-31

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerNCT00785291 · 2008-10-13

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast CancerNCT00601900 · 2008-09-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerNCT00684983 · 2008-07-30

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveNCT00390455 · 2006-09-15

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT00376688 · 2006-07-11

Common interventions

Leading sponsors

National Cancer Institute (NCI) 26 M.D. Anderson Cancer Center 6 City of Hope Medical Center 5 Mayo Clinic 5 University of Washington 3 Alliance for Clinical Trials in Oncology 2 Academic and Community Cancer Research United 1 Fred Hutchinson Cancer Center 1 Ohio State University Comprehensive Cancer Center 1 Rutgers, The State University of New Jersey 1 SWOG Cancer Research Network 1

Trial status mix

COMPLETED23

ACTIVE_NOT_RECRUITING13

TERMINATED10

RECRUITING3

WITHDRAWN2

SUSPENDED1

Phase mix

PHASE225

PHASE122

PHASE36

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.